Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial - Takeaways - MDSpire

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

  • By

  • M Tobiasson

  • I Dybedahl

  • M S Holm

  • M Karimi

  • L Brandefors

  • H Garelius

  • M Grövdal

  • I Högh-Dufva

  • K Grønbæk

  • M Jansson

  • C Marcher

  • L Nilsson

  • A O Kittang

  • A Porwit

  • L Saft

  • L Möllgård

  • E Hellström-Lindberg

  • March 7, 2014

  • 0 min

Share

  • 1

    Azacitidine shows limited efficacy in inducing transfusion independence in transfusion-dependent, growth factor-resistant low- and Int-1-risk MDS patients.

  • 2

    The Nordic NMDSG08A phase II trial enrolled 30 patients, revealing considerable toxicity associated with azacitidine treatment.

  • 3

    Mutational analysis identified common mutations in lower-risk MDS, with TET2 mutations linked to higher response rates to azacitidine.

  • 4

    Patients with a transfusion need of ≥4 units over 8 weeks were included, emphasizing the trial's focus on refractory cases.

  • 5

    The study's primary endpoint was the number of patients achieving transfusion independence after six cycles of azacitidine treatment.

Original Source(s)

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

  • by M Tobiasson, I Dybedahl, M S Holm, M Karimi, L Brandefors, H Garelius, M Grövdal, I Högh-Dufva, K Grønbæk, M Jansson, C Marcher, L Nilsson, A O Kittang, A Porwit, L Saft, L Möllgård, E Hellström-Lindberg

  • March 7, 2014

Related Content

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

Utilizing Erythrocyte Lifespan as a Predictor for Moderate to Severe Anemia in Patients with Advanced Gastric Cancer Following Anti-Tumor Treatments: A Prospective Investigation

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min